SENSEX
NIFTY
GOLD
USD/INR

Weather

image 18    C

Company News

The Economic Times

Company / The Economic Times

details

Sun Pharmas specialty portfolio, Organon deal to drive growth

Sun Pharmaceutical achieved notable revenue growth in the September quarter, driven by strong performance in India and specialty medicines. The company anticipates medium-term growth from therapies like Ilumya and ongoing innovative projects. Although profitability was affected by acquisition and litigation costs, the domestic market share increased to 8.6% from last year. R&D investments are expected to rise in the second half of FY27 as development accelerates.

2 Nov 2026 6:45 am